ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center
Status:
Recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
A novel regimen, which is composed of a low dose of ATG (5 mg/kg) and low-dose PTCy (one dose
of PTCy, 50mg/kg) for GvHD prophylaxis in Haplo-PBSCT for patients with hematologic
malignancies, was designed to decrease the risk of aGvHD and lower the incidence of virus
reactivation.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine